---
title: "ODN-39M and LALF32-51 as nasal adjuvants to boost immune responses to rAg85B"
id: "biorxiv-0-synthetic-adjuvants-to-potentiate-the-immune-response-against-rag85b-by-nasal"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-0-synthetic-adjuvants-to-potentiate-the-immune-response-against-rag85b-by-nasal"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# ODN-39M and LALF32-51 as nasal adjuvants to boost immune responses to rAg85B
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-0-synthetic-adjuvants-to-potentiate-the-immune-response-against-rag85b-by-nasal
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study evaluates two synthetic adjuvants, **ODN-39M** (a CpG oligodeoxynucleotide) and the peptide **LALF32-51**, delivered intranasally with recombinant Ag85B (rAg85B) from Mycobacterium tuberculosis in Balb/C mice. - The rationale is that nasal vaccines can induce both mucosal and systemic immunity and may be useful against respiratory pathogens, including tuberculosis and drug-resistant bacterial variants. - **ODN-39M** potentiated the immune response to rAg85B, driving a preferential **Th1** pattern and inducing potent cell-mediated immunity alongside high **IgA** levels in the lungs and systemic responses. - The vaccine formulation combining **ODN-39M** with Ag85B elicited early recruitment of lymphoid cells in the nasal-associated lymphoid tissue (**NALT**) and increased expression of the activation marker **CD69**, particularly on B cells and dendritic cells. - The report presents preliminary NALT interaction data suggesting early local immune activation, but acknowledges that detailed mechanisms of NALT innate and adaptive responses were not fully elucidated in this work. - The peptide adjuvant **LALF32-51** was evaluated but the abstract emphasizes ODN-39M as the adjuvant that showed clear potentiation; specific comparative data or quantitative outcomes for LALF32-51 were not reported in the abstract. - Authors conclude that the data support the potential use of **ODN-39M** as a potent and potentially safe nasal adjuvant for future vaccines, while noting that further studies are needed to deepen understanding of NALT functioning and local innate responses. - Study context: preclinical work in Balb/C mice; this is a preprint and has not been peer reviewed. Funding was declared from the Science and Technology Innovation Program of Hunan Province (2024RC9030).
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=7_z_.h7LhKr_DzTEYqqfYt4NMApoSPX5ErQqunkzStU-1788553272.3807743-1.2.1.1-3t_jQHfa1yYmgVSrG8H30oh9V3hX.1cpR_8zm7AkqxE4wOHV0ooQxGF1X6i0p4M6) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # Synthetic adjuvants to potentiate the immune response against rAg85B by nasal route. Rong Chen, Changyuan Tan, Wen Li, Yasser Perera, [ View ORCID Profile](http://orcid.org/0000-0003-0318-5111)Yadira Lobaina doi: https://doi.org/10.64898/2026.08.31.748287 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Rong Chen 1 CCBJIC: Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC) Lengshuitan District, Yongzhou City, Hunan, 425000, China; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rong%2BChen%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Chen%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ARong%2BChen%2B) Changyuan Tan 2 Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC) Lengshuitan District, Yongzhou City, Hunan, 425000, China * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Changyuan%2BTan%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Tan%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AChangyuan%2BTan%2B) Wen Li 2 Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC) Lengshuitan District, Yongzhou City, Hunan, 425000, China * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wen%2BLi%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Li%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AWen%2BLi%2B) Yasser Perera 2 Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC) Lengshuitan District, Yongzhou City, Hunan, 425000, China * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yasser%2BPerera%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Perera%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AYasser%2BPerera%2B) Yadira Lobaina 2 Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC) Lengshuitan District, Yongzhou City, Hunan, 425000, China * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yadira%2BLobaina%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Lobaina%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AYadira%2BLobaina%2B) * [ORCID record for Yadira Lobaina](http://orcid.org/0000-0003-0318-5111 "Open in new tab") * For correspondence: ylobainamato@ccbjic.com * [Abstract](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5756739/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5756739/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5756739/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5756739/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Respiratory infections remain a relevant global health concern nowadays. The rapid dissemination and high mutational ratio of some pathogens, amid human demographic drivers, increases their pandemic potential. On the other hand, some bacterial infections have re-emerged with new resistant variants, supporting the need of updated or more potent vaccines. The development of nasal vaccines, with the capacity to efficiently induce immune response at the respiratory tract and systemic compartments, constitutes an appealing strategy to tackle respiratory infections, including tuberculosis. In this work, two synthetic compounds, the ODN-39M and the peptide LALF32-51, are evaluated as nasal vaccine adjuvants for the Ag85B antigen from Mycobacterium tuberculosis. The capacity of such adjuvants to enhance the immune response at systemic and mucosal compartments following intranasal immunization was assessed in Balb/C mice. The ODN-39M was able to potentiate the immune response, showing preferentially a Th1 pattern. The vaccine preparation containing this CpG adjuvant plus Ag85B induces potent cell-mediated and high IgA specific antibody response in lungs, along with systemic immunity. A preliminary study of the interaction between the ODN-39M with the NALT immune cells shows the early recruitment of lymphoid cells, and the increase of CD69 activation marker, mainly in B and dendritic cells. Although further studies should be done to reach a deeper understanding of NALT functioning, including the development of local innate response, the current data enrich the scarce reports focused on this compartment and support the use of the ODN-39M as a potent and potentially safe adjuvant option for future nasal vaccines. ### Competing Interest Statement The authors have declared no competing interest. ## Funder Information Declared The Science and Technology Innovation Program of Hunan Province, 2024RC9030 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.08.31.748352v1 "Alpha-linolenic acid and dietary protein minimally but differentially regulate white adipose tissue lipolysis in female mice fed moderate-fat diets")[Next ](https://www.biorxiv.org/content/10.64898/2026.08.31.748303v1 "siProGenA: Generative siRNA Candidate Construction via Position Proposal and Guide Generation") Posted September 04, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.08.31.748287v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/09/04/2026.08.31.748287.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) Synthetic adjuvants to potentiate the immune response against rAg85B by nasal route. Rong Chen, Changyuan Tan, Wen Li, Yasser Perera, Yadira Lobaina bioRxiv 2026.08.31.748287; doi: https://doi.org/10.64898/2026.08.31.748287 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.31.748287v1%26text%3DSynthetic%2520adjuvants%2520to%2520potentiate%2520the%2520immune%2520response%2520against%2520rAg85B%2520by%2520nasal%2520route. "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.31.748287v1%26t%3DSynthetic%2520adjuvants%2520to%2520potentiate%2520the%2520immune%2520response%2520against%2520rAg85B%2520by%2520nasal%2520route. "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.31.748287v1%26title%3DSynthetic%2520adjuvants%2520to%2520potentiate%2520the%2520immune%2520response%2520against%2520rAg85B%2520by%2520nasal%2520route.%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.31.748287v1%26title%3DSynthetic%2520adjuvants%2520to%2520potentiate%2520the%2520immune%2520response%2520against%2520rAg85B%2520by%2520nasal%2520route. "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.08.31.748287) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.biorxiv.org/content/10.64898/2026.08.31.748287v1&count=horizontal&via=&text=Synthetic%20adjuvants%20to%20potentiate%20the%20immune%20response%20against%20rAg85B%20by%20nasal%20route.&counturl=www.biorxiv.org/content/10.64898/2026.08.31.748287v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.biorxiv.org/content/early/recent) * [Animal Behavior and Cognition](https://www.biorxiv.org/collection/animal-behavior-and-cognition) (7962) * [Biochemistry](https://www.biorxiv.org/collection/biochemistry) (18613) * [Bioengineering](https://www.biorxiv.org/collection/bioengineering) (14759) * [Bioinformatics](https://www.biorxiv.org/collection/bioinformatics) (44103) * [Biophysics](https://www.biorxiv.org/collection/biophysics) (22441) * [Cancer Biology](https://www.biorxiv.org/collection/cancer-biology) (19579) * [Cell Biology](https://www.biorxiv.org/collection/cell-biology) (26727) * [Clinical Trials](https://www.biorxiv.org/collection/clinical-trials) (138) * [Developmental Biolog
## Related Clinical Research

- [Predicting TB relapse from 28-day CFU and RS ratio in the relapsing mouse model](https://medichelpline.com/clinical-feed/biorxiv-4-predicting-tuberculosis-relapse-based-on-28-day-cfu-rs-ratio-and-or-drug.md)
- [DAG-HEART: DAG-Guided Transfer Learning to Improve Equity-Aware Breast Cancer Prediction](https://medichelpline.com/clinical-feed/biorxiv-0-dag-heart-directed-acyclic-graph-guided-health-equity-aware-representation.md)
- [Emergency diagnosis frequency and outcomes across 13 non-cancer conditions in England: analysis of](https://medichelpline.com/clinical-feed/plos-medicine-2-frequency-and-prognostic-outcomes-of-emergency-diagnosis-in-13-non-neoplastic.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Saliva-based nanopore sequencing panel for pharmacogenomic screening in drug-resistant tuberculosis](https://medichelpline.com/clinical-feed/medrxiv-5-nanopore-sequencing-panel-for-saliva-based-host-pharmacogenomic-screening-in.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.